MedDataX Logo

Clinical Application of Quantitative Ultrasonographic Analysis in Early Kidney Injury

NCT ID: NCT05662774

Last Updated: 2022-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to quantify overall blood flow and renal cortical perfusion in patients with septic acute kidney injury (AKI) using ultrasound (US) Doppler and contrast-enhanced ultrasound (CEUS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Kidney ultrasound is the most widely used imaging modality in initial AKI workup as it is widely available and free of complications. It is clinically feasible to use US Doppler and contrast-enhanced US (CEUS) to detect macroscopic and microscopic changes in renal blood flow, and also cardiac output alterations.The aim was to analyze changes in US Doppler and CEUS quantitative parameters in patients with septic AKI to explore perfusion within the renal parenchyma, and also measure global renal blood flow and cardiac output.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patient Admitted to Hospital With Acute Kidney Injury Due to Sepsis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Acute kidney injury contrast-enhanced ultrasound renal perfusion microcirculation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultrasound contrast agent (Sonovue)

Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Meets the AKI diagnostic criteria of the Kidney Disease: Improving Global Outcomes (KDIGO)
2. Meets Sepsis 3.0 diagnostic criteria for sepsis: infection + SOFA ≥ 2

Exclusion Criteria

1. Urinary tract obstruction, hydronephrosis, etc.
2. Left ventricular ejection fraction \<30% (measured by transthoracic echocardiography), systolic pulmonary artery pressure \>90 mmHg (measured by transthoracic echocardiography)
3. Allergy or adverse reaction to contrast media
Minimum Eligible Age

19 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Second Affiliated Hospital of Soochow University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

The Second Hospital of Soochow University The Second Hospital of Soochow University

Role: STUDY_CHAIR

The Second Hospital of Soochow University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Second Hospital of Soochow University

Suzhou, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peiqing Liu

Role: CONTACT

Phone: +8618625268629

Email: [email protected]

Yunzhu YU

Role: CONTACT

Phone: +8613382147113

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Peiqing Liu

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JD-HG-2021-40

Identifier Type: -

Identifier Source: org_study_id